ClinicalTrials.gg
RecruitingNCT04875429Updated Oct 6, 2026

Zenith® Fenestrated+ Clinical Study

An interventional study of Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2 in Aortic Aneurysm, Abdominal, Juxtarenal Aortic Aneurysm and Extent IV Thoracoabdominal, sponsored by Cook Research Incorporated. Recruiting at 33 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Cook Research Incorporated (part of Cook Group Incorporated) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
105
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 16 studies in Aortic Aneurysm, Abdominal by Cook Group Incorporated — 1 open to participants now, 1 under way, none of them phase 3. Aortic Aneurysm, Abdominal · Cook Group Incorporated.

Planned enrollment
3rd of 11
105 · median 42
Started
2023
the only one that year
No phase
11 of 16
1 open now
Registered
16th of 16
by date

Among the 16 studies in Aortic Aneurysm, Abdominal by Cook Group Incorporated, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2023, is one of 11 with no phase, and was the 16th registered.

Aortic Aneurysm, Abdominal

467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.

Browse Aortic Aneurysm, Abdominal studies →

Open to participants now

1 of the 16 studies in Aortic Aneurysm, Abdominal by Cook Group Incorporated is open now, in 2 countries.

By country, each count listing its studies:

Who these studies take

Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Aortic Aneurysm, Abdominal by Cook Group Incorporated, or all of them as a file.
02

Study summary

The Zenith® Fenestrated+ Endovascular Graft Clinical Study will assess the safety and effectiveness of the Zenith® Fenestrated+ Endovascular Graft (ZFEN+) in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System (BeGraft) and Unibody2 for the treatment of patients with aortic aneurysms involving one or more of the major visceral arteries.

Up to 130 additional subjects may be enrolled in Continued Access phase of the study

03

Conditions studied

  • Aortic Aneurysm, Abdominal
  • Juxtarenal Aortic Aneurysm
  • Extent IV Thoracoabdominal
  • Pararenal Aneurysm

Keywords

  • endovascular
  • Vascular Diseases
  • Cardiovascular Diseases
  • Fenestration
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Include Criteria:

  1. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with a diameter ≥ 55 mm for males and ≥ 50 mm for females
  2. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with a growth rate of ≥ 5 mm in 6 months
  3. Thoracoabdominal, pararenal or juxtarenal aortic aneurysm with aortic diameter > 2x the normal aortic diameter or saccular aneurysm that warrants treatment in the opinion of the investigator

Exclusion Criteria:

  1. Age \< 18 years
  2. \< 2 years
  3. Pregnant, breast-feeding, or planning to become pregnant within 60 months
  4. Inability or refusal to give by the patient or legally authorized representative
  5. Unwilling or unable to comply with the follow-up schedule, required clinical assessments, and imaging
  6. Simultaneous participation in another investigation study, unless the patient is at least 30 days beyond the primary endpoint of any previous study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
105 participants (estimated)

Study arms

  • Experimental
    Aortic abdominal aneurysm

    Device: Zenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2

Interventions

  • DeviceZenith Fenestrated+ Endovascular Graft in combination with the BeGraft Balloon-Expandable FEVAR Bridging Stent Graft System and Unibody2

    Endovascular aneurysm repair

06

What researchers measure

Primary outcomes

  1. Composite measure of device technical success and procedural safety

    Percent of patients with device technical success and freedom from procedural safety events in the following criteria: 1. Device technical success which includes delivery, deployment, and withdrawal of the device without the need for unanticipated corrective intervention), and 2. Freedom from the following procedural safety events: rupture, aneurysm-related mortality, permanent paraplegia, new onset renal failure requiring dialysis, bowel ischemia requiring surgery, and disabling stroke

    Time frame: 30 days post procedure

  2. Composite measure of freedom from aneurysm-related mortality and clinically significant reintervention

    Percent of patients meeting the following criteria: 1. Freedom from aneurysm-related mortality (death from aneurysm rupture, death from any cause occurring within 30 days of procedure or secondary intervention or device or procedure related death) and 2. Freedom from clinically significant reintervention (including open surgery to restore blood flow or restore bodily function, any device related intervention requiring hospitalization, placement of an additional endovascular graft component(s), placement of a stent(s) as indicated for loss of or for having inadequate fixation, seal or patency)

    Time frame: 12 months post procedure

07

Study locations

30 of 33 sites recruiting
  • University of Alabama Birmingham Hospital
    Birmingham, Alabama 35294, United States
    Recruiting
    • Adam Beck, MD · Contact
  • UC San Diego
    La Jolla, California 92037, United States
    Recruiting
    • Mahmoud Malas, MD · Contact
  • University of Southern California
    Los Angeles, California 90031, United States
    Recruiting
    • Sukgu Han, MD · Contact
  • Stanford Hospitals and Clinics
    Stanford, California 94305, United States
    Recruiting
    • Jason Lee, MD · Contact
  • Medstar Washington Hospital Center
    Washington D.C., District of Columbia 20010, United States
    Recruiting
    • Steven Abramowitz, MD · Contact
  • University of Florida Shands Hospital
    Gainesville, Florida 32610, United States
    Recruiting
    • Zain Shahid, MD · Contact
  • Tampa General Hospital
    Tampa, Florida 33606, United States
    Recruiting
    • Dean Arnaoutakis, MD · Contact
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
    Recruiting
    • Yazan Duwayri, MD · Contact
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
    Recruiting
    • Neel Mansukhani, MD · Contact
  • Endeavor Health Cardiovascular Institute at Glenbrook Hospital
    Glenview, Illinois 60026, United States
    Recruiting
    • George Pontikis · Contact
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
    Recruiting
    • Michael Soult, MD · Contact
  • Edward Hospital
    Naperville, Illinois 60540, United States
    Recruiting
    • George Pontikis, MD · Contact
    • George Pontikis, MD · Principal investigator
  • Methodist Hospital of Indiana
    Indianapolis, Indiana 46202, United States
    Recruiting
    • Andres Fajardo, MD · Contact
  • University of Maryland
    Baltimore, Maryland 21201, United States
    Recruiting
    • Shahab Toursavadkohi, MD · Contact
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
    Completed

    Not enrolling at this site — choose another above.

  • Beth Israel Deaconess Medical Center
    Boston, Massachusetts 02215, United States
    Recruiting
    • Marc Schermerhorn, MD · Contact
  • University of Massachusetts
    Worcester, Massachusetts 01655, United States
    Recruiting
    • Andres Schanzer, MD · Contact
  • University of Michigan Health System
    Ann Arbor, Michigan 48109, United States
    Recruiting
    • Jonathan Eliason, MD · Contact
  • Mayo Clinic
    Rochester, Minnesota 55905, United States
    Recruiting
    • Randall DeMartino, MD · Contact
  • Barnes Jewish Hospital
    St Louis, Missouri 63110, United States
    Recruiting
    • John Ohman, MD · Contact
  • Dartmouth-Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
    Recruiting
    • Bjoern Suckow, MD · Contact
  • New York University Langone Medical Center
    New York, New York 10016, United States
    Recruiting
    • Thomas Maldonado, MD · Contact
  • Columbia University Irving Medical Center/NY Presbyterian Hospital
    New York, New York 10032, United States
    Recruiting
    • Virenda Patel · Contact
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27599, United States
    Recruiting
    • Federico Parodi, MD · Contact
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
    Recruiting
    • Francis Caputo, MD · Contact
  • Hospital of the University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Grace Wang, MD · Contact
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
    • Nathan Liang · Contact
  • Medical University of South Carolina
    Charleston, South Carolina 29425, United States
    Recruiting
    • Ravi Veeraswamy, MD · Contact
  • Holston Valley Hospital
    Kingsport, Tennessee 37660, United States
    Recruiting
    • Robert "Bo" Allen, MD · Contact
  • Ut Southwestern
    Dallas, Texas 75235, United States
    Recruiting
    • Mirza Baig, MD · Contact
  • Memorial Hermann Texas Medical Center/UT Health
    Houston, Texas 77030, United States
    Recruiting
    • Naveed Saqib, MD · Contact
  • Carilion Roanoke Memorial Hospital
    Roanoke, Virginia 24014, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • St Thomas' Hospital
    London, SE1 7EH, United Kingdom
    Active, not recruiting

    Not enrolling at this site — choose another above.

08

References and documents

Individual participant data

Plan to share: Undecided — Cook Research Incorporated (CRI) is fully committed to supporting the principles of responsible data sharing, including providing qualified scientific researchers access to deidentified, patient-level data from CRI clinical studies to conduct legitimate scientific research. Data underlying the results reported in this clinical study will be made available for request after publication of the results from this study and ending 5 years after initial publication. Interested researchers may review the "Cook Research Incorporated Policy on Access to Clinical Study Data" at https://www.cookresearchinc.com/extranet/data-access.html and submit a complete research proposal to request data access. Additional study documents (such as the study protocol) will be shared as needed if the data access request is granted. A data sharing agreement will be executed for access to deidentified patient-level data.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Nov 2026, 35 months after the start.

Of 43 industry-sponsored interventional studies with no phase under Aortic Aneurysm, Abdominal, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 73. This study's planned 35 months is below that.

Counting every sponsor, half of 94 studies reached it within 43 months; a quarter within 23 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
May 6, 2021
StartActual
Dec 8, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2031
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date and description
1 update, last Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    Minor edits only
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04875429
Responsible party
Sponsor
First posted
May 6, 2021
Start date
Dec 8, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2031 (estimated)
Last update
Oct 6, 2026

Study contacts

Chanda Bell, RN, BSN
Contact
chanda.bell@cookmedical.com
765-463-7537 ext. 321506
Maria Soerensen
Contact
maria.soerensen@cookmedical.com
+45 2868 3248
Gustavo Oderich, MD
principal investigator · Baylor College of Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion